相似文献
1
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
J Hematol Oncol. 2021 Apr 21;14(1):66. doi: 10.1186/s13045-021-01077-3.
2
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.
Exp Hematol Oncol. 2022 Sep 24;11(1):61. doi: 10.1186/s40164-022-00316-8.
3
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Exp Hematol Oncol. 2024 Feb 27;13(1):25. doi: 10.1186/s40164-024-00485-8.
4
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.
5
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Front Immunol. 2022 Mar 7;13:839097. doi: 10.3389/fimmu.2022.839097. eCollection 2022.
6
Cancer biomarkers for targeted therapy.
Biomark Res. 2019 Nov 15;7:25. doi: 10.1186/s40364-019-0178-7. eCollection 2019.
7
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.
Exp Hematol Oncol. 2024 Apr 18;13(1):43. doi: 10.1186/s40164-024-00508-4.
8
CAR T-Cell Therapy Shows Promise in Multiple Hematologic Malignancies.
Oncology (Williston Park). 2020 Jan 15;34(1):20.
9
Progress on CAR-T cell therapy for hematological malignancies.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Apr 25;51(2):192-203. doi: 10.3724/zdxbyxb-2022-0055.
10
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
J Hematol Oncol. 2018 Dec 21;11(1):142. doi: 10.1186/s13045-018-0684-3.
引用本文的文献
1
Nano-orchestrated magnetotactic-like navigation for electromagnetic theranostics and immune enhancement via photoautotrophic oxygenation, mild hyperthermia, and ferroptosis.
J Nanobiotechnology. 2025 Jun 13;23(1):442. doi: 10.1186/s12951-025-03488-7.
2
Human Mesenchymal Stem Cell-Derived Exosomes as Engineering Vehicles of Daunorubicin for Targeted c-Mpl+ AML Therapy.
Int J Nanomedicine. 2025 Apr 24;20:5267-5289. doi: 10.2147/IJN.S511713. eCollection 2025.
3
Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.
Int J Mol Sci. 2024 Oct 31;25(21):11735. doi: 10.3390/ijms252111735.
4
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes.
Biomark Res. 2024 Oct 8;12(1):115. doi: 10.1186/s40364-024-00665-y.
5
Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1025. doi: 10.3390/ph17081025.
6
Engineered Antibodies as Cancer Radiotheranostics.
Adv Sci (Weinh). 2024 Aug;11(30):e2402361. doi: 10.1002/advs.202402361. Epub 2024 Jun 14.
7
A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.
Bioeng Transl Med. 2023 Nov 9;9(2):e10601. doi: 10.1002/btm2.10601. eCollection 2024 Mar.
8
Therapeutic Immunomodulation in Gastric Cancer.
Cancers (Basel). 2024 Jan 28;16(3):560. doi: 10.3390/cancers16030560.
9
Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022).
Pharmaceuticals (Basel). 2023 Aug 15;16(8):1162. doi: 10.3390/ph16081162.
10
Immunotherapy in leukaemia.
Acta Biochim Biophys Sin (Shanghai). 2023 Jun 2;55(6):974-987. doi: 10.3724/abbs.2023101.
本文引用的文献
1
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655.
2
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood. 2021 Jul 1;137(26):3616-3628. doi: 10.1182/blood.2020008787.
3
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
4
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
J Clin Oncol. 2021 Apr 10;39(11):1203-1213. doi: 10.1200/JCO.20.02666. Epub 2021 Jan 14.
5
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
Exp Hematol Oncol. 2021 Jan 4;10(1):1. doi: 10.1186/s40164-020-00186-y.
6
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent.
Front Pharmacol. 2020 Nov 26;11:564108. doi: 10.3389/fphar.2020.564108. eCollection 2020.
7
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
J Hematol Oncol. 2020 Dec 7;13(1):168. doi: 10.1186/s13045-020-00998-9.
8
Natural killer cell-based immunotherapy for acute myeloid leukemia.
J Hematol Oncol. 2020 Dec 7;13(1):167. doi: 10.1186/s13045-020-00996-x.
9
Novel therapeutics in myeloproliferative neoplasms.
J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y.
10
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
J Hematol Oncol. 2020 Nov 30;13(1):160. doi: 10.1186/s13045-020-00989-w.
Zotero 插件